Olympus says fixing issues raised by U.S. FDA about facilities in Japan

[January 12, 2023]  (Reuters) - Olympus Corp, a Japanese medical device maker, said it was taking action to address concerns raised by the U.S. health regulator related to violations found during the inspection of the company's facilities in Japan.

The U.S. Food and Drug Administration (FDA) said on Monday it had issued warning letters to Olympus' units pertaining to a category of devices known as endoscopes, citing violations at its facilities.

Olympus said it was making changes to the quality systems at its facilities.

Responses to each warning letter have been submitted to FDA, and the actions to fix the issues is progressing, a company spokesperson said in an emailed response late Wednesday.

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

(Reporting by Raghav Mahobe in Bengaluru; Editing by Shailesh Kuber)

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.